Cancer-Presented Work

Presentations

Society for Immunotherapy of Cancer’s Annual Meeting & Associated Programs, National Harbor, November 8-12, 2017

 

American Association of Immunologists - IMMUNOLOGY 2017, Washington, DC, May 12-16, 2017

 

American Association for Cancer Research (AACR) 2017, Washington, DC, April 1-5, 2017

 

Keystone Symposium on Cancer Immunology and Immunotherapy, Whistler, British Columbia, March 19-23, 2017

 

Neoantigen Summit, Boston, November 15-17, 2016

 

Society of Immunotherapy of Cancer’s Annual Meeting & Associated Programs, National Harbor, November 9-13, 2016

 

Society for Immunotherapy of Cancer’s Annual Meeting & Associated Programs in National Harbor, November 7, 2015

 

Publications

Antigen-Screening System - Perfecting the Promise of T Cell Therapies for Infectious Disease & Cancer 

Flechtner, JB (2016) Drug Development & Delivery epub June 2016

This article describes Genocea’s proprietary ATLASTM technology, illustrating how finding the RIGHT targets of T cell responses matters for successful immunotherapies and vaccines.  The article describes how ATLAS had yielded an HSV-2 immunotherapy that has shown unprecedented efficacy in Phase 2 clinical trials and then introduces emerging cancer immunotherapy programs that highlight the ways ATLAS is poised to revolutionize immuno-oncology.

 

Improving Cancer Immunotherapies through Empirical Neoantigen Selection

Nogueira, C et al. (2018) Trends in Cancer epub January 2018

This concise review summarizes the importance of empirical identification of neoantigens to overcome the shortcomings of in silico antigen predictions and describes the limited technologies available for the biological prioritization of true neoantigens. Genocea’s ATLAS™ technology is showcased as a high-throughput, reliable solution to identify the true antigens of T cells from any subject that can be incorporated into novel immunotherapies.